55
Participants
Start Date
June 30, 2011
Primary Completion Date
November 30, 2018
Study Completion Date
March 31, 2019
Herceptin+XELOX
"Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression~* Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks~* Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Oxaliplatin 130 mg/m2 i.v. on day 1"
Asan Medical Center, Seoul
Lead Sponsor
Hoffmann-La Roche
INDUSTRY
Asan Medical Center
OTHER